497 related articles for article (PubMed ID: 15367588)
21. Smallpox subunit vaccine produced in Planta confers protection in mice.
Golovkin M; Spitsin S; Andrianov V; Smirnov Y; Xiao Y; Pogrebnyak N; Markley K; Brodzik R; Gleba Y; Isaacs SN; Koprowski H
Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6864-9. PubMed ID: 17428917
[TBL] [Abstract][Full Text] [Related]
22. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model.
Chen Z; Earl P; Americo J; Damon I; Smith SK; Yu F; Sebrell A; Emerson S; Cohen G; Eisenberg RJ; Gorshkova I; Schuck P; Satterfield W; Moss B; Purcell R
J Virol; 2007 Sep; 81(17):8989-95. PubMed ID: 17581986
[TBL] [Abstract][Full Text] [Related]
23. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
24. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
[TBL] [Abstract][Full Text] [Related]
25. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
[TBL] [Abstract][Full Text] [Related]
26. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
Viner KM; Girgis N; Kwak H; Isaacs SN
Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
[TBL] [Abstract][Full Text] [Related]
27. Improved protection against Venezuelan equine encephalitis by genetic engineering of a recombinant vaccinia virus.
Bennett AM; Lescott T; Phillpotts RJ
Viral Immunol; 1998; 11(3):109-17. PubMed ID: 9918402
[TBL] [Abstract][Full Text] [Related]
28. The immune response to vaccinia virus is significantly reduced after scarification with TK- recombinants as compared to wild-type virus.
Phillpotts RJ; Lescott T; Gates AJ; Jones L
Acta Virol; 2000; 44(3):151-6. PubMed ID: 11155357
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models.
Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Shivachandra SB
Antiviral Res; 2016 Feb; 126():108-16. PubMed ID: 26723250
[TBL] [Abstract][Full Text] [Related]
30. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
[TBL] [Abstract][Full Text] [Related]
31. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
Hooper JW; Custer DM; Thompson E
Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
[TBL] [Abstract][Full Text] [Related]
32. Immune responses to mucosal vaccination by the recombinant A1 and N proteins of infectious bronchitis virus.
Meir R; Krispel S; Simanov L; Eliahu D; Maharat O; Pitcovski J
Viral Immunol; 2012 Feb; 25(1):55-62. PubMed ID: 22225471
[TBL] [Abstract][Full Text] [Related]
33. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement.
Lustig S; Fogg C; Whitbeck JC; Moss B
Virology; 2004 Oct; 328(1):30-5. PubMed ID: 15380355
[TBL] [Abstract][Full Text] [Related]
34. Immunologic analysis induced by DNA vaccine encoding E protein of Beijing-1 strain derived from Japanese encephalitis virus.
Feng GH; Liu N; Zhou Y; Zhai YZ; Li XM; Dou XG
Intervirology; 2007; 50(2):93-8. PubMed ID: 17139185
[TBL] [Abstract][Full Text] [Related]
35. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
[TBL] [Abstract][Full Text] [Related]
36. Interaction between vaccinia virus extracellular virus envelope A33 and B5 glycoproteins.
Perdiguero B; Blasco R
J Virol; 2006 Sep; 80(17):8763-77. PubMed ID: 16912323
[TBL] [Abstract][Full Text] [Related]
37. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
[TBL] [Abstract][Full Text] [Related]
38. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant.
Chaitra MG; Nayak R; Shaila MS
Vaccine; 2007 Oct; 25(41):7168-76. PubMed ID: 17709160
[TBL] [Abstract][Full Text] [Related]
39. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
40. Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.
Cohen ME; Xiao Y; Eisenberg RJ; Cohen GH; Isaacs SN
PLoS One; 2011; 6(6):e20597. PubMed ID: 21687676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
